20 March 2020
Visiongain has launched a new pharma report: Pharma Clinical Trial Services Market and Industry Forecast 2020-2030: Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Disease.
This report encompasses the global market for pharmaceutical clinical trial services. It provides a comprehensive and critical analysis of the market, including the subsectors of early phase services and late phase services. The report also assesses the key therapeutic areas in which leading clinical research organizations (CROs) operate, namely, cancer, cardiovascular disease, CNS disease, infectious diseases and metabolic disease.
The lead analyst of the report commented "Biotech, pharmaceutical & medical device companies continue to develop at a fast pace owing to continuous expenditure on R&D, rising demand for biopharmaceuticals and increased healthcare needs for the geriatric population. In order to fulfil this, the demand for effective clinical trials has increased in order to ensure the effectiveness and safety of products. This demand is further propelled by the increasing importance of contract research organizations in emerging markets. The main challenges faced in this market are the lengthy authorisation, and approval procedures imposed by regulatory authorities."
Leading companies featured in the report include Quintiles, Laboratory Corporation of America (LabCorp), Pharmaceutical Product Development (PPD), Parexel International, ICON, INC Research Holdings, inVentiv Health & Other Companies
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.